BioNTech’s stock is caught in a tug-of-war between a robust $1 billion share buyback program and a deepening legal quagmire that now includes a fresh patent lawsuit from Sanofi. The Mainz-based biotech, which rode the COVID-19 vaccine wave to global prominence, is navigating a period where its pipeline progress and financial maneuvers are increasingly overshadowed by courtroom battles.
Sanofi filed a lawsuit on July 22, 2026, in a New Jersey federal court, accusing Pfizer and Moderna of infringing patents related to lipid nanoparticle technology originally held by Translate Bio—a company Sanofi acquired for $3.2 billion in 2021. The French drugmaker is seeking damages and a jury trial. Moderna has vowed to defend itself, while Pfizer has yet to comment. This case adds to a growing list of legal challenges that directly involve BioNTech, which co-developed and markets the COVID-19 vaccine Comirnaty with Pfizer. Already, Bayer sued both Pfizer and BioNTech in January 2026, and separate lawsuits from Arbutus Biopharma and Genevant over similar lipid nanoparticle technology remain active. The financial stakes are clear: Moderna previously settled with Alnylam, Genevant, and Arbutus for $950 million, while Pfizer paid $320 million to settle a dispute with GSK.
The legal noise comes at a time when BioNTech’s financial performance has been underwhelming. First-quarter 2026 revenue came in at $136.71 million, missing analyst estimates of $207.42 million by roughly 35% and falling 35.4% year-over-year. The loss per share of $2.26 was narrower than the expected $2.52 deficit, offering a sliver of relief. In response, the board authorized a $1 billion share buyback program in early May—a move often interpreted by investors as a vote of confidence in the company’s intrinsic value, especially when operational results disappoint.
Analyst sentiment remains divided, though the consensus leans positive. Among 19 analysts covering the stock, the average rating is “Moderate Buy,” with 13 recommending “Buy,” one “Strong Buy,” four “Hold,” and one “Sell.” The average price target stands at $129.13, but the range is wide. HC Wainwright reiterated a $130 target in late April, while Morgan Stanley cut its target to $119 in July, albeit maintaining an overweight rating. Canaccord Genuity lowered its target from $171 to $158 in May but kept a buy rating, and Berenberg trimmed from $155 to $140, also retaining a buy. Jefferies and UBS added to the bullish camp in late May, with price targets of $138 and $135, respectively, citing progress in BioNTech’s oncology pipeline, including data presented at the ASCO conference in mid-May.
Should investors sell immediately? Or is it worth buying BioNTech?
The stock’s performance reflects the uncertainty. In Frankfurt, shares traded at €80.85 on the day, up 0.50%, but remain 23.58% below the 52-week high of €105.80 reached in late January. The gap to the 200-day moving average is 4.53%, signaling that the medium-term trend is still fragile. Since hitting a 52-week low of €68.35 in March, the stock has recovered somewhat, but the combination of patent litigation, mixed analyst calls, and a revenue miss has kept a lid on momentum.
The broader biotech sector is buzzing with M&A activity, with 37 deals worth at least $1 billion each totaling $216 billion in the first seven months of 2026. GSK bought Nuvalent for $10.6 billion, Eli Lilly acquired AtaiBeckley for up to $3.8 billion, and Novartis picked up Myricx Bio. The focus on platform technologies, where BioNTech’s mRNA expertise fits, has sparked speculation, though the company has not been named as a target in the current wave.
Adding to the mix, the ARK fund led by Cathie Wood reportedly sold BioNTech shares recently, while labor union criticism of the company’s culture made headlines in late May. Shareholders, however, approved all agenda items at the annual general meeting in mid-May. The next major catalyst is the second-quarter 2026 earnings report, due August 4, which will show whether the revenue trend is stabilizing. For now, BioNTech’s story is one of a company trying to prove its pipeline promise while fending off legal claims that could drain resources and distract management. The buyback signals confidence, but the courtroom calendar may ultimately dictate the stock’s direction.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from July 23 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 23.
BioNTech: Buy or sell? Read more here...
